Literature DB >> 25922696

Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?

Daniela Morales-Espinosa1, Rafael Rosell1.   

Abstract

Entities:  

Year:  2015        PMID： 25922696      PMCID： PMC4387398          DOI： 10.3978/j.issn.2072-1439.2015.01.34

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Authors:  Tomoya Kawaguchi; Masahiko Ando; Kazuhiro Asami; Yoshio Okano; Masaaki Fukuda; Hideyuki Nakagawa; Hidenori Ibata; Toshiyuki Kozuki; Takeo Endo; Atsuhisa Tamura; Mitsuhiro Kamimura; Kazuhiro Sakamoto; Michihiro Yoshimi; Yoshifumi Soejima; Yoshio Tomizawa; Shun-ichi Isa; Minoru Takada; Hideo Saka; Akihito Kubo
Journal:  J Clin Oncol       Date:  2014-05-19       Impact factor: 44.544

2.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Reck; S Popat; N Reinmuth; D De Ruysscher; K M Kerr; S Peters
Journal:  Ann Oncol       Date:  2014-08-11       Impact factor: 32.976

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Authors:  Dae Ho Lee; Keunchil Park; Joo Hang Kim; Jong-Seok Lee; Sang Won Shin; Jin-Hyoung Kang; Myung-Ju Ahn; Jin Seok Ahn; Cheolwon Suh; Sang-We Kim
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

6.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

7.  Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.

Authors:  Jong-Mu Sun; Ki Hyeong Lee; Sang-We Kim; Dae Ho Lee; Young Joo Min; Hwan Jung Yun; Hoon Kyo Kim; Hong Suk Song; Yeul Hong Kim; Bong-Seog Kim; In Gyu Hwang; Keehyun Lee; Sook Jung Jo; Jae Won Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

8.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Authors:  Riichiroh Maruyama; Yutaka Nishiwaki; Tomohide Tamura; Nobuyuki Yamamoto; Masahiro Tsuboi; Kazuhiko Nakagawa; Tetsu Shinkai; Shunichi Negoro; Fumio Imamura; Kenji Eguchi; Koji Takeda; Akira Inoue; Keisuke Tomii; Masao Harada; Noriyuki Masuda; Haiyi Jiang; Yohji Itoh; Yukito Ichinose; Nagahiro Saijo; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

9.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

10.  Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Authors:  Jean-Yves Douillard; Frances A Shepherd; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Mei-Lin Liao; Helge Bischoff; Martin Reck; Mark V Sellers; Claire L Watkins; Georgina Speake; Alison A Armour; Edward S Kim
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.